Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

C2269000

Clindamycin phosphate

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

Clindamycin 2-phosphate, Clindamycin 2-dihydrogen phosphate

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

250 MG
133,00 €

133,00 €

Per informazioni sulla disponibilità, contatta il Servizio Clienti.
Richiedi un ordine bulk
Tutte le immagini(1)

Scegli un formato

Cambia visualizzazione
250 MG
133,00 €

About This Item

Formula empirica (notazione di Hill):
C18H34ClN2O8PS
Numero CAS:
24729-96-2
Peso molecolare:
504.96
Numero CE:
246-433-0
Numero MDL:
MFCD07793328
Codice UNSPSC:
41116107
ID PubChem:
329774986
NACRES:
NA.24

133,00 €

Per informazioni sulla disponibilità, contatta il Servizio Clienti.
Richiedi un ordine bulk

Grado

pharmaceutical primary standard

Famiglia di API

clindamycin

Produttore/marchio commerciale

EDQM

tecniche

HPLC: suitable
gas chromatography (GC): suitable

applicazioni

pharmaceutical (small molecule)

Formato

neat

Stringa SMILE

CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC([C@H](C)Cl)C2O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]2O

InChI

1S/C18H34ClN2O8PS/c1-5-6-10-7-11(21(3)8-10)17(24)20-12(9(2)19)15-13(22)14(23)16(18(28-15)31-4)29-30(25,26)27/h9-16,18,22-23H,5-8H2,1-4H3,(H,20,24)(H2,25,26,27)/t9-,10+,11-,12?,13+,14-,15?,16+,18+/m0/s1
UFUVLHLTWXBHGZ-MWBQRTRKSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Clindamycin phosphate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Azioni biochim/fisiol

Spectrum of Activity: Gram positive cocci and taxoplasma. Especially active against anaerobic bacteria.
Mode of Action: Inhibits protein synthesis in bacterial by binding the 50s ribosomal subunit.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Antibacterial and antiprotozoal antibiotic of the licosamide class.
Sales restrictions may apply.

Pittogrammi

Exclamation mark
GHS07

Avvertenze

Warning

Indicazioni di pericolo

H302,H317,H319,H362

Classi di pericolo

Acute Tox. 4 Oral - Eye Irrit. 2 - Lact. - Skin Sens. 1

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 4

1 of 4

Ciprofloxacin hydrochloride European Pharmacopoeia (EP) Reference Standard

C2190000

Ciprofloxacin hydrochloride

Clindamicina lincosamide antibiotic

Sigma-Aldrich

C5269

Clindamicina

Permethrin (25:75) European Pharmacopoeia (EP) Reference Standard

Y0001733

Permethrin (25:75)

Cefotaxime sodium salt suitable for plant cell culture, BioReagent, powder or crystals

Sigma-Aldrich

C7039

Cefotaxime sodium salt

Diane Thiboutot et al.
Journal of the American Academy of Dermatology, 59(5), 792-800 (2008-09-23)
We sought to evaluate efficacy, safety, and tolerability of a combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% (clindamycin-BPO 2.5%) aqueous gel in moderate to severe acne vulgaris. A total of 2813 patients, aged 12 years or older, were
M Badawy Abdel-Naser et al.
Expert opinion on pharmacotherapy, 9(16), 2931-2937 (2008-10-22)
Clindamycin phosphate 1.2% together with tretinoin 0.025% as a gel (CTG) is a topical formulation of a fixed and stable combination approved by the FDA for the treatment of acne vulgaris in patients 12 years of age or older. The
Lawrence F Eichenfield et al.
Pediatric dermatology, 26(3), 257-261 (2009-08-27)
Treatments for mild to moderately severe acne usually combine retinoid and antimicrobial therapy. Recently, the US FDA approved the combination of 1.2% clindamycin (CLIN) and 0.025% tretinoin (RA) in a novel gel formulation for the treatment of mild to moderate
Azadeh Ghaffari et al.
International wound journal, 9(2), 221-229 (2011-12-08)
Ethanol that affects hydration of skin and used in wound treatment formulations was studied here for its effect on permeation of drugs through burn eschar and to investigate the presence of a porous pathway in this barrier. In this study
Asuka Munehiro et al.
The Journal of dermatological treatment, 23(3), 172-176 (2011-07-16)
Cosmetic moisturisers were applied to one side of the face of 18 male Japanese patients with acne vulgaris who were treated with a topical administration of adapalene and clindamycin phosphate gels. We assessed the alleviating effect of the moisturisers on
Visualizza tutti i documenti correlati

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.